The Readout Loud
281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future of Sarepta and the retirement of a biotech stalwart.
For more on what we cover, here's where you can read Frank's work; here's more on Sarepta; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here's where you can subscribe to our biotech newsletter, The Readout.